Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Liabilities and Shareholders Equity: 2021-2025

  • Abivax's Liabilities and Shareholders Equity fell 55.80% to $135.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $836.7 million, marking a year-over-year decrease of 2.74%. This contributed to the annual value of $219.3 million for FY2024, which is 37.68% down from last year.
  • Abivax's Liabilities and Shareholders Equity amounted to $135.4 million in Q2 2025, which was down 22.88% from $175.6 million recorded in Q1 2025.
  • Abivax's 5-year Liabilities and Shareholders Equity high stood at $351.9 million for Q4 2023, and its period low was $77.1 million during Q4 2022.
  • In the last 3 years, Abivax's Liabilities and Shareholders Equity had a median value of $219.3 million in 2024 and averaged $237.7 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 356.58% in 2023, then plummeted by 55.80% in 2025.
  • Abivax's Liabilities and Shareholders Equity (Quarterly) stood at $125.0 million in 2021, then tumbled by 38.32% to $77.1 million in 2022, then surged by 356.58% to $351.9 million in 2023, then plummeted by 37.68% to $219.3 million in 2024, then crashed by 55.80% to $135.4 million in 2025.
  • Its last three reported values are $135.4 million in Q2 2025, $175.6 million for Q1 2025, and $219.3 million during Q4 2024.